Fernando Perrone - Profarma Distribuidora Independent Director
| PFRM3 Stock | BRL 5.45 0.10 1.87% |
Director
Mr. Fernando Perrone has served as an Independent Member of the Board of Directors of Profarma Distribuidora de Produtos Farmaceuticos SA since April 3, 2008. He also holds positions within Grupo Metalnave, the Brazilian Association of the Infrastructure and Capital Goods Industries and the Getulio Vargas Foundation . He also acts as Consultant in the airport sector and is Member of CSNs Audit Committee. Prior to this, he was Chief Executive Officer of INFRAERO and Executive Officer in the Infrastructure and Administration Areas of the National Bank for Social and Economic Development BNDES, where he was also Head of Privatizations. He also served as Chief Executive Officer at Banco de Estado da Paraiba, Executive Officer at BDRio and ABDE and Chief Operations Officer of Banco Denasa de Investimento. He gained a degree in Economics from Fundacao Getulio Vargas and in Law from Universidade Federal Fluminense. since 2008.
| Age | 70 |
| Tenure | 16 years |
| Phone | 55 21 4009 0200 |
| Web | https://www.profarma.com.br |
Profarma Distribuidora Management Efficiency
The company has return on total asset (ROA) of 0.0368 % which means that it generated a profit of $0.0368 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0645 %, meaning that it generated $0.0645 on every $100 dollars invested by stockholders. Profarma Distribuidora's management efficiency ratios could be used to measure how well Profarma Distribuidora manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Victor Foroni | JHSF Participaes SA | N/A | |
| Douglas Duarte | Tecnisa SA | N/A | |
| Luiz Belluzzo | JHSF Participaes SA | 69 | |
| Pedro Malan | Mills Estruturas e | 71 | |
| Diego Bush | Mills Estruturas e | N/A | |
| Thiago Oliveira | JHSF Participaes SA | 52 | |
| Fabio Bruggioni | Mills Estruturas e | N/A | |
| Roberto Pedote | Mills Estruturas e | N/A | |
| Richard Barczinski | JHSF Participaes SA | N/A | |
| Ruben Formighieri | Positivo Tecnologia SA | 56 | |
| Fernando Mitri | Positivo Tecnologia SA | 66 | |
| Roberto Monteiro | Tecnisa SA | 43 | |
| Daniel Brugioni | Mills Estruturas e | N/A | |
| Carlos Ambrosio | JHSF Participaes SA | N/A | |
| Alvaro Amaral | Positivo Tecnologia SA | 62 | |
| Gustavo Zeno | Mills Estruturas e | N/A | |
| Francisca Nacht | Mills Estruturas e | N/A | |
| Aymar Almeida | Mills Estruturas e | N/A | |
| Samuel Lago | Positivo Tecnologia SA | 45 | |
| Claudio Bonomi | JHSF Participaes SA | N/A | |
| Nicolas Wollak | Mills Estruturas e | N/A | |
Management Performance
| Return On Equity | 0.0645 | |||
| Return On Asset | 0.0368 |
Profarma Distribuidora Leadership Team
Elected by the shareholders, the Profarma Distribuidora's board of directors comprises two types of representatives: Profarma Distribuidora inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Profarma. The board's role is to monitor Profarma Distribuidora's management team and ensure that shareholders' interests are well served. Profarma Distribuidora's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Profarma Distribuidora's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sammy Birmarcker, CEO, Member of the Executive Board, Chairman of the Board | ||
| Armando Martins, Director | ||
| Fernando Perrone, Independent Director | ||
| Adriano Prado, Member Officers | ||
| Maximiliano Fischer, CFO, Director of Investor Relations, Member of the Executive Board | ||
| Dan Ioschpe, Independent Director | ||
| Manoel Birmarcker, Vice Chairman of the Board |
Profarma Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Profarma Distribuidora a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0645 | |||
| Return On Asset | 0.0368 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | 0.03 % | |||
| Current Valuation | 1.35 B | |||
| Shares Outstanding | 122.61 M | |||
| Shares Owned By Insiders | 66.17 % | |||
| Shares Owned By Institutions | 26.52 % | |||
| Price To Earning | (6.45) X | |||
| Price To Book | 0.35 X |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Profarma Distribuidora using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Profarma Distribuidora de. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the Profarma Distribuidora information on this page should be used as a complementary analysis to other Profarma Distribuidora's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Complementary Tools for Profarma Stock analysis
When running Profarma Distribuidora's price analysis, check to measure Profarma Distribuidora's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Profarma Distribuidora is operating at the current time. Most of Profarma Distribuidora's value examination focuses on studying past and present price action to predict the probability of Profarma Distribuidora's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Profarma Distribuidora's price. Additionally, you may evaluate how the addition of Profarma Distribuidora to your portfolios can decrease your overall portfolio volatility.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |